Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens

Molecular Cancer Therapeutics

Volumn 11, Issue 12, 2012, Pages 2664-2673

  Friedrich, Matthias ^a   Raum, Tobias ^b   Lutterbuese, Ralf ^a   Voelkel, Markus ^a   Deegen, Petra ^a   Rau, Doris ^a   Kischel, Roman ^a   Hoffmann, Patrick ^a   Brandl, Christian ^a   Schuhmacher, Joachim ^b   Mueller, Peter ^a   Finnern, Ricarda ^b   Fuergut, Melanie ^a   Zopf, Dieter ^b   Slootstra, Jerry W ^c   Baeuerle, Patrick A ^a   Rattel, Benno ^a   Kufer, Peter ^a  

^a Amgen Research GmbH   (Germany)

^b BAYER PHARMA AG   (Germany)

^c Pepscan Presto ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 212; ANTIBODY; ANTINEOPLASTIC AGENT; BAY 2010112; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, SURFACE; CHO CELLS; CRICETINAE; CROSS REACTIONS; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HAPLORHINI; HUMANS; IMMUNIZATION, PASSIVE; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; PROSTATIC NEOPLASMS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871360414     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0042     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007;51:1175-84. (Pubitemid 46436320)
3. Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2005;2:174-82. (Pubitemid 40823138)
4. Elsasser-Beile U, Buhler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009;10:118-25.
5. Mohammed AA, Shergill IS, Vandal MT, Gujral SS. ProstaScint and its role in the diagnosis of prostate cancer. Expert Rev Mol Diagn 2007;7:345-9. (Pubitemid 47066550)
6. Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, et al. Current vaccination strategies for prostate cancer. Eur Urol 2012;61:290-306.
7. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-7.
8. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-8.
9. Buhler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother 2008;57:43-52. (Pubitemid 350043647)
10. Buhler P, Molnar E, Dopfer EP, Wolf P, Gierschner D, Wetterauer U, et al. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells. J Immunother 2009;32:565-73.
11. Fortmuller K, Alt K, Gierschner D, Wolf P, Baum V, Freudenberg N, et al. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA x CD3 bispecific single-chain diabody. Prostate 2011;71:588-96.
12. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A 2010;107:12605-10.
13. Knappe A, Feldmann G, Dittmer U, Meinl E, Nisslein T, Wittmann S, et al. Herpesvirus saimiri-transformed macaque T cells are tolerated and do not cause lymphoma after autologous reinfusion. Blood 2000;95:3256-61. (Pubitemid 30321182)
14. Slootstra JW, Puijk WC, Ligtvoet GJ, Langeveld JP, Meloen RH. Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Mol Divers 1996;1:87-96.
15. Raum T, Gruber R, Riethmuller G, Kufer P. Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens. Cancer Immunol Immunother 2001;50:141-50. (Pubitemid 32480558)
16. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978;6:547-58.
17. Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 1979;68:1071-4. (Pubitemid 10099391)
18. Bernard J, Harb C, Mortier E, Quemener A, Meloen RH, Vermot-Desroches C, et al. Identification of an interleukin-15alpha receptor-binding site on human interleukin-15. J Biol Chem 2004;279:24313-22. (Pubitemid 38725294)
19. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71. (Pubitemid 43939148)
20. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A 2005;102:5981-6. (Pubitemid 40594241)
21. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007;30:798-807. (Pubitemid 350295358)
22. Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010;37:533-46.
23. Kipriyanov SM, Moldenhauer G, Martin AC, Kupriyanova OA, Little M. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng 1997;10:445-53. (Pubitemid 27252636)